Protein S-100B: a prognostic marker for cerebral damage

The assessment of S-100B in acute neurological disorders such as global hypoxia, ischaemic or haemorrhagic stroke and traumatic brain injury reflects severity of symptoms and outcome. However, the temporal profile of S-100B release depends on topography, intensity and pathophysiology of the damage e...

Full description

Saved in:
Bibliographic Details
Main Authors: Stroick, Mark Gregor (Author) , Fatar, Marc (Author) , Ragoschke-Schumm, Andreas (Author) , Faßbender, Klaus (Author) , Bertsch, Thomas (Author) , Hennerici, Michael G. (Author)
Format: Article (Journal)
Language:English
Published: 2006
In: Current medicinal chemistry
Year: 2006, Volume: 13, Issue: 25, Pages: 3053-3060
ISSN:1875-533X
DOI:10.2174/092986706778521751
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2174/092986706778521751
Get full text
Author Notes:Mark Stroick, Marc Fatar, Andreas Ragoschke-Schumm, Klaus Fassbender, Thomas Bertsch, Michael G. Hennerici
Description
Summary:The assessment of S-100B in acute neurological disorders such as global hypoxia, ischaemic or haemorrhagic stroke and traumatic brain injury reflects severity of symptoms and outcome. However, the temporal profile of S-100B release depends on topography, intensity and pathophysiology of the damage e.g. immediate release after traumatic brain injury following the acute destruction of neuronal tissue or delayed release after ischaemic stroke in which gradual breakdown of the blood-brain barrier plays a crucial role. In chronic brain diseases, knowledge about the clinical value of quantification of S-100B is scarce and further evaluations are needed. This review considers both conditions for S-100B measurement and illustrates advantages and limitations in comparison with clinical and neuroimaging data.
Item Description:Gesehen am 06.05.2022
Physical Description:Online Resource
ISSN:1875-533X
DOI:10.2174/092986706778521751